Stephen Thorne
![Stephen Thorne Stephen Thorne](https://oncolytic-virotherapy-summit.com/wp-content/uploads/sites/149/2023/07/Stephen-Thorne-150x150.jpg)
Company: KaliVir Immunotherapeutics
Job title: Chief Scientific Officer
Seminars:
VET3-TGI, a TGF-Beta Targeting Clinical Oncolytic Virus Developed from the VET Platform for Systemic Delivery 2:30 pm
• KaliVir has developed the VET platform to develop oncolytic virus backbones capable of achieving systemic delivery to solid tumors • VET3-TGI represents the lead internal product from this platform and is undergoing clinical translational development • In addition to unique intravenous delivery capabilities, VET3-TGI targets TGF-beta within the tumor microenvironment • Pre-clinical data with…Read more
day: Day One